

# Marco Moia

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5765861/publications.pdf>

Version: 2024-02-01

86  
papers

8,096  
citations

81743

39  
h-index

56606

83  
g-index

86  
all docs

86  
docs citations

86  
times ranked

6042  
citing authors

#	ARTICLE	IF	CITATIONS
1	The effect of health literacy on vaccine hesitancy among Italian anticoagulated population during COVID-19 pandemic: the moderating role of health engagement. <i>Human Vaccines and Immunotherapeutics</i> , 2024, 17, 5007-5012.	1.4	11
2	Determinants of health-related quality of life: a cross-sectional investigation in physician-managed anticoagulated patients using vitamin K antagonists. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 73.	1.0	6
3	Anticoagulation Knowledge Tool (AKT): Further evidence of validity in the Italian population. <i>PLoS ONE</i> , 2018, 13, e0201476.	1.1	5
4	Position Paper on laboratory testing for patients on direct oral anticoagulants. A Consensus Document from the Siset, FCSA, SIBioC and SIPMeL. <i>Blood Transfusion</i> , 2018, 16, 462-470.	0.3	54
5	Vitamin K antagonist therapy: changes in the treated populations and in management results in Italian anticoagulation clinics compared with those recorded 20 years ago. <i>Internal and Emergency Medicine</i> , 2017, 12, 1109-1119.	1.0	30
6	Thrombophilic risk of individuals with rare compound factor V Leiden and prothrombin G20210A polymorphisms: an international case series of 100 individuals. <i>European Journal of Haematology</i> , 2016, 97, 353-360.	1.1	10
7	Coagulation parameters in patients with cirrhosis and portal vein thrombosis treated sequentially with low molecular weight heparin and vitamin K antagonists. <i>Digestive and Liver Disease</i> , 2016, 48, 1208-1213.	0.4	20
8	Does Sex Affect Anticoagulant Use for Stroke Prevention in Nonvalvular Atrial Fibrillation?. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, S12-20.	0.9	74
9	Laboratory tests during direct oral anticoagulant treatment. <i>Internal and Emergency Medicine</i> , 2014, 9, 903-905.	1.0	2
10	New oral anticoagulants in thrombotic antiphospholipid syndrome. <i>Lupus</i> , 2014, 23, 1279-1282.	0.8	34
11	Comments on: Laboratory tests for the management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants: Proposals of the Working Group on Perioperative Haemostasis (GIHP). <i>Archives of Cardiovascular Diseases</i> , 2014, 107, 345-346.	0.7	3
12	D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study. <i>Blood</i> , 2014, 124, 196-203.	0.6	160
13	Prevalence of Peripheral Artery Disease by Abnormal Ankle-Brachial Index in Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2013, 62, 2255-2256.	1.2	49
14	Differential diagnosis of pulmonary embolism in outpatients with non-specific cardiopulmonary symptoms. <i>Internal and Emergency Medicine</i> , 2013, 8, 695-702.	1.0	16
15	Prevalence of risk factors for venous thromboembolism in the Italian population: results of a cross-sectional study from the Master Registry. <i>Internal and Emergency Medicine</i> , 2013, 8, 575-580.	1.0	11
16	Patient preferences and willingness to pay for different options of anticoagulant therapy. <i>Internal and Emergency Medicine</i> , 2013, 8, 237-243.	1.0	31
17	Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1979-1987.	1.9	29
18	The accuracy of the International Normalized Ratio and the American College of Chest Physicians recommendations on the use of vitamin K to reverse over-anticoagulation. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 2207-2208.	1.9	1

#	ARTICLE	IF	CITATIONS
19	Safety and efficacy of low-dose fondaparinux (1.5 mg) for the prevention of venous thromboembolism in acutely ill medical patients with renal impairment: the FONDAIR study. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 2291-2297.	1.9	21
20	Long-term death and recurrence in patients with acute venous thromboembolism: The MASTER registry. <i>Thrombosis Research</i> , 2012, 130, 369-373.	0.8	33
21	Biological variation of INR in stable patients on long-term anticoagulation with warfarin. <i>Thrombosis Research</i> , 2012, 130, 535-537.	0.8	10
22	Aspirin for Preventing the Recurrence of Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2012, 366, 1959-1967.	13.9	545
23	The prothrombin time/international normalized ratio (PT/INR) Line: derivation of local INR with commercial thromboplastins and coagulometers – two independent studies. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 140-148.	1.9	21
24	Risk factors for catheter-related thrombosis (CRT) in cancer patients: a patient-level data (IPD) meta-analysis of clinical trials and prospective studies. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 312-319.	1.9	181
25	False-negative or false-positive: laboratory diagnosis of lupus anticoagulant at the time of commencement of anticoagulant: a rebuttal. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 1435-1436.	1.9	8
26	Extended prophylaxis of venous thromboembolism with fondaparinux in patients undergoing major orthopaedic surgery in Italy: a cost-effectiveness analysis. <i>Internal and Emergency Medicine</i> , 2010, 5, 33-40.	1.0	14
27	Combined oral anticoagulant and antiplatelet treatment: need for an evidence-based approach. <i>Internal and Emergency Medicine</i> , 2010, 5, 275-276.	1.0	0
28	More on: new antithrombotics: a need for laboratory monitoring. For or against. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 2087-2088.	1.9	1
29	Duration of anticoagulant treatment and recurrence of venous thromboembolism in patients with and without thrombophilic abnormalities. <i>Thrombosis and Haemostasis</i> , 2009, 101, 596-598.	1.8	6
30	A multicentre randomised assessment of the DAWN AC computer-assisted oral anticoagulant dosage program. <i>Thrombosis and Haemostasis</i> , 2009, 101, 487-494.	1.8	45
31	Standardized Low-Molecular-Weight Heparin Bridging Regimen in Outpatients on Oral Anticoagulants Undergoing Invasive Procedure or Surgery. <i>Circulation</i> , 2009, 119, 2920-2927.	1.6	133
32	Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, Part 1: Prevention. <i>American Journal of Hematology</i> , 2009, 84, 579-583.	2.0	28
33	The cost-effectiveness of computer-assisted anticoagulant dosage: results from the European Action on Anticoagulation (EAA) multicentre study. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 1482-1490.	1.9	26
34	Renal allograft thrombosis. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 1388-1393.	0.4	75
35	Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. <i>Lancet Oncology</i> , The, 2009, 10, 943-949.	5.1	538
36	Dabigatran versus warfarin in patients with atrial fibrillation. <i>New England Journal of Medicine</i> , 2009, 361, 2672; author reply 2674-5.	13.9	2

#	ARTICLE	IF	CITATIONS
37	An international multicenter randomized study of computer-assisted oral anticoagulant dosage vs. medical staff dosage. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 935-943.	1.9	98
38	A multicentre randomised clinical endpoint study of <scp>parma</scp> 5 computer-assisted oral anticoagulant dosage. <i>British Journal of Haematology</i> , 2008, 143, 274-283.	1.2	23
39	The MASTER registry on venous thromboembolism: Description of the study cohort. <i>Thrombosis Research</i> , 2008, 121, 605-610.	0.8	79
40	Factors associated with the timing of diagnosis of venous thromboembolism: Results from the MASTER registry. <i>Thrombosis Research</i> , 2008, 121, 751-756.	0.8	49
41	Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. <i>Lancet, The</i> , 2008, 371, 315-321.	6.3	257
42	Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry. <i>Haematologica</i> , 2008, 93, 273-278.	1.7	123
43	Risk factors for venous thromboembolism in the elderly: results of the master registry. <i>Blood Coagulation and Fibrinolysis</i> , 2008, 19, 663-667.	0.5	25
44	A commentary: To screen for calf DVT or not to screen? The highly variable practice among Italian centers highlights this important and still unresolved clinical option. Results from the Italian MASTER registry. <i>Thrombosis and Haemostasis</i> , 2008, 99, 241-244.	1.8	18
45	Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1327-1333.	0.5	184
46	A Clinical Outcome-Based Prospective Study on Venous Thromboembolism After Cancer Surgery. <i>Annals of Surgery</i> , 2006, 243, 89-95.	2.1	595
47	Oral surgery in patients on oral anticoagulant therapy: a randomized comparison of different INR targets. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 688-689.	1.9	25
48	The first ambulatory screening on thromboembolism: a multicentre, cross-sectional, observational study on risk factors for venous thromboembolism. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 1459-1466.	1.9	81
49	Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study. <i>British Journal of Haematology</i> , 2005, 129, 811-817.	1.2	134
50	Thrombophilic abnormalities and recurrence of venous thromboembolism in patients treated with standardized anticoagulant treatment. <i>Thrombosis Research</i> , 2005, 116, 301-306.	0.8	52
51	CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, 198-203.	2.3	90
52	Catheter-related thrombosis in hematologic patients. <i>Reviews in Clinical and Experimental Hematology</i> , 2004, 8, E5.	0.1	0
53	Heparin-induced thrombocytopenia and warfarin-induced skin necrosis in a child with severe protein C deficiency: successful treatment with dermatan sulfate and protein C concentrate. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 387-388.	1.9	19
54	Incidence of cancer after a first episode of idiopathic venous thromboembolism treated with 3 months or 1 year of oral anticoagulation. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 1730-1733.	1.9	72

#	ARTICLE	IF	CITATIONS
55	Warfarin and acenocoumarol dose requirements according to CYP2C9 genotyping in North-Italian patients. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 2252-2253.	1.9	12
56	Prevention of Venous Thrombosis with Elastic Stockings During Long-Haul Flights: The LONFLIT 5 JAP Study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2003, 9, 197-201.	0.7	42
57	The LONFLIT4-Concorde - Sigvaris Traveno Stockings in Long Flights (EcoTraS) Study. <i>Angiology</i> , 2003, 54, 1-9.	0.8	41
58	The LONFLIT4-Concorde Deep Venous Thrombosis and Edema Study: Prevention with Travel Stockings. <i>Angiology</i> , 2003, 54, 143-154.	0.8	40
59	Venous thromboembolism in the antiphospholipid syndrome: management guidelines for secondary prophylaxis. <i>Lupus</i> , 2003, 12, 504-507.	0.8	41
60	Central Venous Catheter-related Complications in Patients with Hematological Malignancies: A Retrospective Analysis of Risk Factors and Prophylactic Measures. <i>Leukemia and Lymphoma</i> , 2003, 44, 1495-1501.	0.6	41
61	Prevention of Edema, Flight Microangiopathy and Venous Thrombosis in Long Flights with Elastic Stockings. A Randomized Trial. <i>Angiology</i> , 2002, 53, 635-645.	0.8	76
62	Venous Thrombosis from Air Travel: The LONFLIT3 Study. <i>Angiology</i> , 2002, 53, 1-6.	0.8	213
63	Three Months versus One Year of Oral Anticoagulant Therapy for Idiopathic Deep Venous Thrombosis. <i>New England Journal of Medicine</i> , 2001, 345, 165-169.	13.9	567
64	Analysis of the tissue factor pathway inhibitor gene and antigen levels in relation to venous thrombosis. <i>British Journal of Haematology</i> , 2001, 113, 537-543.	1.2	51
65	The G1691A mutation of factor V, but not the G20210A mutation of factor II or the C677T mutation of methylenetetrahydrofolate reductase genes, is associated with venous thrombosis in patients with lupus anticoagulants. <i>British Journal of Haematology</i> , 2000, 108, 865-870.	1.2	40
66	A Comparison of the Safety and Efficacy of Oral Anticoagulation for the Treatment of Venous Thromboembolic Disease in Patients with or without Malignancy. <i>Thrombosis and Haemostasis</i> , 2000, 84, 805-810.	1.8	208
67	Oral Anticoagulation Treatment in the Elderly. <i>Archives of Internal Medicine</i> , 2000, 160, 470.	4.3	119
68	Accuracy of a Portable Prothrombin Time Monitor (Coagucheck) in Patients on Chronic Oral Anticoagulant Therapy. <i>Thrombosis Research</i> , 2000, 100, 279-286.	0.8	47
69	D-dimer testing as an adjunct to ultrasonography in patients with clinically suspected deep vein thrombosis: prospective cohort study. <i>BMJ: British Medical Journal</i> , 1998, 317, 1037-1040.	2.4	192
70	Congenital Resistance to Activated Protein C in Patients with Lupus Anticoagulants: Evaluation of Two Functional Assays. <i>Thrombosis and Haemostasis</i> , 1998, 80, 246-249.	1.8	12
71	Budd-Chiari Syndrome in a Patient Heterozygous for the G20210A Mutation of the Prothrombin Gene. <i>Thrombosis and Haemostasis</i> , 1998, 79, 445-446.	1.8	26
72	Occult Cancer and Venous Thromboembolism. <i>Thrombosis and Haemostasis</i> , 1998, 80, 347-348.	1.8	0

#	ARTICLE	IF	CITATIONS
73	Thrombotic Events during Oral Anticoagulant Treatment: Results of the Inception-cohort, Prospective, Collaborative ISCOAT Study. <i>Thrombosis and Haemostasis</i> , 1997, 78, 1438-1443.	1.8	77
74	Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: A four-year prospective study from the italian registry. <i>American Journal of Medicine</i> , 1996, 100, 530-536.	0.6	426
75	Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). <i>Lancet, The</i> , 1996, 348, 423-428.	6.3	1,270
76	Prognostic value of the activated partial thromboplastin time after orthotopic liver transplantation. <i>International Journal of Clinical and Laboratory Research</i> , 1994, 24, 220-222.	1.0	2
77	Prognostic value of the activated partial thromboplastin time after orthotopic liver transplantation: a prospective study. <i>Journal of Hepatology</i> , 1994, 21, 917.	1.8	1
78	Type I von Willebrand disease, subtype "platelet low": decreased platelet adhesion can be explained by low synthesis of von Willebrand factor in endothelial cells. <i>British Journal of Haematology</i> , 1993, 83, 88-93.	1.2	26
79	Ischemic stroke in congenital (type II C) defective antithrombin III. <i>International Journal of Clinical and Laboratory Research</i> , 1993, 23, 212-214.	1.0	3
80	Laboratory Measures of Hemostasis for Monitoring Liver Graft Function. <i>Seminars in Thrombosis and Hemostasis</i> , 1993, 19, 238-242.	1.5	3
81	Effects of Hirudin on Activated Partial Thromboplastin Time Determined with Ten Different Reagents. <i>Thrombosis and Haemostasis</i> , 1993, 70, 286-288.	1.8	33
82	Prognostic value of hemostatic parameters after liver transplantation. <i>Journal of Hepatology</i> , 1992, 15, 125-128.	1.8	16
83	Effects of subcutaneously administered dermatan sulfate (MF 701) on the coagulation and fibrinolytic parameters of healthy volunteers. <i>Thrombosis Research</i> , 1991, 62, 663-672.	0.8	8
84	Role for platelet von willebrand factor in supporting platelet-vessel wall interactions in von willebrand disease. <i>American Journal of Hematology</i> , 1989, 31, 153-158.	2.0	17
85	IMPROVEMENT IN THE HAEMOSTATIC DEFECT OF URAEMIA AFTER TREATMENT WITH RECOMBINANT HUMAN ERYTHROPOIETIN. <i>Lancet, The</i> , 1987, 330, 1227-1229.	6.3	236
86	Correction of the bleeding time in treated patients with severe von willebrand disease is not solely dependent on the normal multimeric structure of plasma von willebrand factor. <i>American Journal of Hematology</i> , 1987, 25, 55-65.	2.0	53